"I would just say that our program is enrolling well, and we expect
to be able to see clinical data in the back half of the year,"
Merck's Chief Executive Officer Robert Davis said at Morgan
Stanley's Annual Global Healthcare Conference.
Merck and partner Ridgeback Biotherapeutics are conducting a
late-stage trial of molnupiravir in non-hospitalized COVID-19
patients to see if it reduces the risk of hospitalization or death.
[to top of second column] |
Merck in June said it expected
to file for the emergency use authorization of
molnupiravir in the second half of 2021 at the
earliest.
(Reporting by Manojna Maddipatla in Bengaluru;
Editing by Shailesh Kuber)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |